HSP60 activity has been previously demonstrated in glioblastoma [65], and the results reveal that HSP60 silencing inhibits glioma progression via deactivation of the mTOR pathway, suggesting that HSP60 is a possible therapeutic target for the treatment of glioblastoma [74]. This evidence concerns the gene HSPD1 and central nervous system cancer.